The fifth revised edition of this highly successful book presents the most extensive enhancement since *Using and Understanding Medical Statistics* was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the 'heavy lifting'.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis, and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

**Contents**

Preface to the Fifth Edition
Prefaces to the Previous Editions

- Basic Concepts
- Tests of Significance
- Fisher's Test for $2 \times 2$ Contingency Tables
- Approximate Significance Tests for Contingency Tables
- Some Warnings concerning $2 \times 2$ Tables
- Kaplan-Meier or 'Actuarial' Survival Curves
- The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
- An Introduction to the Normal Distribution
- Analyzing Normally Distributed Data
- Linear Regression Models for Medical Data
- Binary Logistic Regression
- Regression Models for Count Data
- Proportional Hazards Regression
- The Analysis of Longitudinal Data
- Analysis of Variance
- Data Analysis
- The Question of Sample Size
- The Design of Clinical Trials
- Further Comments regarding Clinical Trials
- Meta-Analysis
- Epidemiological Applications
- Diagnostic Tests
- Agreement and Reliability

References
Subject Index

![QR Code](https://example.com)
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as “Chemotherapia” by H.P. Kuemmerle and P. Rentchnick

Editor-in-Chief

G. Minotti, Rome

Associate Editors

G. Delogu, Rome
G. Graziani, Rome

Editorial Board

A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing

R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

The founder of chemotherapy

Paul Ehrlich
1854–1915

Karger

Printed in Germany on acid-free and non-aging paper
(ISO 9706) by Stückle Druck, Ettenheim
Guidelines for Authors

Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission. A Copyright Transfer Form, available on the Submission Website, with the corresponding author's original (hand-written) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.icmje.org/)

In case of problems with submission, please contact: che@karger.com

S. Karger AG – Medical and Scientific Publishers
Editorial Office “Chemotherapy”
Allschwilerstrasse 10
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approve the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Chemistry and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest
Authors are required to disclose any sponsorship or funding arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified in the text.

Ethics
Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation.

If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Full documentation. Reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bulleted points and established facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Short Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. Accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, tables and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1,200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PDF, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.

KARGER
© 2017 S. Karger AG, Basel
E-Mail Karger@karger.com
The Guidelines for Authors are available at: www.karger.com/che_Guidelines
www.karger.com

Chemotherapy
General Information

ISSN Print Edition: 0009–3157
ISSN Online Edition: 1421–9794

Journal Homepage: www.karger.com/che
Publication Data: Chemotherapy is published 6 times a year. Volume 62 with 6 issues appears in 2017.
Copyright: © 2017 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates:
- Personal subscription:
  - Print or Online: CHF 1232.00; EUR 1110.00; USD 1339.00
  - Print+Online combined: CHF 1282.00; EUR 1150.00; USD 1393.00
- Institutional subscription:
  - Print or Online: CHF 2463.00; EUR 2219.00; USD 2677.00
  - Print+Online combined: CHF 2832.00; EUR 2552.00; USD 3079.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Change of Address:
Both old and new address should be sent to the subscription source.

Photo of Paul Ehrlich on inner title page
Courtesy of the Paul-Ehrlich-Institute, Langen, Germany
Contents

See the journal website for contents
This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information.

Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.
Antimicrobial Section

Original Papers

231 Anaemia following Artemisinin-Based Combination Treatments of Uncomplicated Plasmodium falci-parum Malaria in Children: Temporal Patterns of Haematocrit and the Use of Uncomplicated Hyperparasitaemia as a Model for Evaluating Late-Appearing Anaemia
Sowunmi, A. (Abuja/Ibadan); Akano, K. (Ibadan); Ntadom, G. (Abuja); Ayede, A. (Ibadan); Ogueche, S. (Abuja/Jos); Agomo, C. (Abuja/Lagos); Okafor, H. (Abuja/Enugu); Watila, I. (Abuja/Maiduguri); Meremikwu, M. (Abuja/Calabar); Ogala, W. (Abuja/Zaria); Agomo, P. (Abuja/Lagos); Adowoye, E. (Ibadan); Fatunmbi, B. (Phnom Penh); Aderoyeje, T. (Ibadan); Happi, C. (Abuja/Ede); Gbotosho, G. (Ibadan); Folarin, O. (Ede)

256 Ten-Year Trends and Clinical Relevance of the Antimicrobial Resistance Genotype in Respiratory Isolates of Streptococcus pneumoniae

262 An Uncommon ST1224 NDM-1-Producing Klebsiella pneumoniae Isolated from the Bloodstream of a Leukemia Patient in China

Anticancer Section

Original Papers

205 Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy
Kotake, M. (Shibukawa); Miura, Y.; Imai, H. (Ohta); Mori, K. (Shizuoka); Sakurai, R. (Shibukawa); Kaira, K. (Maebashi); Tomizawa, Y. (Shibukawa); Minato, K. (Ohta); Saito, R. (Shibukawa); Hisada, T. (Maebashi)

215 Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen
Naito, M.; Yamamoto, T.; Shimamoto, C.; Miwa, Y. (Osaka)

225 Dynamics of L-Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy

239 Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents
Kogo, M.; Sunaga, T.; Nakamura, S. (Tokyo/Kanagawa); Akita, T. (Uokohama); Kurihara, T. (Tokyo/Kanagawa); Shikama, Y.; Nakajima, H. (Tokyo); Tobe, T. (Uokohama); Yoneyama, K. (Tokyo); Kiuchi, Y. (Uokohama)

246 Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy

Letter to the Editor

214 Expanding the Role of Chloroquine as a Potent Antineoplastic Agent in Different Gastrointestinal Malignancies
Kapoor, S. (Atlanta, GA)